A Phase 1b Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetic of AMG 479 with Biologics or Chemotherapy in Adult Subjects with Advanced Solid Tumors.

Trial Profile

A Phase 1b Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetic of AMG 479 with Biologics or Chemotherapy in Adult Subjects with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Ganitumab (Primary) ; Bevacizumab; Erlotinib; Gemcitabine; Panitumumab; Sorafenib
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 29 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
    • 27 Mar 2010 Planned end date changed from 1 Oct 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top